Ginkgo Bioworks Holdings Inc (DNA) Price

Dr. Jason Kelly is the Chief Executive Officer of Ginkgo Bioworks Holdings Inc, joining the firm since 2021.

The current price of DNA is $11.39, it has decreased 0.26% in the last trading day.

Ginkgo Bioworks Holdings Inc belongs to Life Sciences Tools & Services industry and the sector is Health Care

Ginkgo Bioworks Holdings Inc's current market cap is $640.1M

According to wall street analysts, 4 analysts have made analyst ratings for Ginkgo Bioworks Holdings Inc, including 0 strong buy, 1 buy, 2 hold, 5 sell, and 0 strong sell

Looks like you're trying to catch a falling knife, anon. Ginkgo Bioworks (DNA) is dropping today, down over 4%, thanks to a cocktail of bearish analyst sentiment and a recent insider sale filing that soured the mood. The technicals aren't looking hot either, with the price threatening a key support level.

The stock is moving on a combination of negative sentiment and technical weakness, with no major positive news to prop it up. Here's the breakdown:

• Price Action & Technicals: DNA is currently trading at $10.01, a drop of 4.12% for the day. It's hovering just above its daily low of $9.95 and approaching a critical daily support level at $9.27. A break below this support could signal more downside. While the overall daily technical signal is "neutral," the underlying trend is weak, and on an hourly basis, the price is trading below its 20-hour and 50-hour moving averages, which is a bearish sign for short-term momentum.

• Sentiment is in the Gutter: The primary driver here is overwhelmingly negative sentiment.

  • Analyst Consensus: Wall Street analysts have a "SELL" recommendation on the stock. For September, out of 11 analysts, 8 have a "Sell" or "Strong Sell" rating. This consensus has been trending more bearish for over a year, which is a major red flag.
  • Insider Selling: A Form 144 was filed around September 10th, indicating an insider's intent to sell shares. While the amount was small, any sign of insiders cashing out can spook the market, especially when sentiment is already fragile.

• No News is Bad News: There has been no significant positive company news in the past week to counter the bearish pressure. While the company has a long-term positive narrative around its use of AI in biotech, it's not enough to fight the current downtrend.

The bottom line is that DNA is fighting an uphill battle against poor sentiment and weak technicals. Trying to long this right now is a high-risk, contrarian play.

Maybe stop trying to be a hero and find a stock that isn't actively being dumped by insiders and analysts. Check the sentiment scores on Edgen Radar before you get rekt, babe.